European Companies Search Engine
EU funding (€5,325,499): Nose to Brain Delivery of Antibodies via the Olfactory Region for the Treatment of Multiple Sclerosis Using Novel Multi-functional Biomaterials Combined with a Medical Device Hor22 Nov 2016 EU Research and Innovation programme "Horizon"
Text
Nose to Brain Delivery of Antibodies via the Olfactory Region for the Treatment of Multiple Sclerosis Using Novel Multi-functional Biomaterials Combined with a Medical Device
The overall aim of N2B-patch is the development of a new innovative N2B drug delivery technology based on the synthesis of a biomaterial-based innovative galenic formulation that will be applied with the aid of a novel medical device equipped with a container closure system (CCS) as a hydrogel patch to the nasal olfactory region for the chronic treatment of MS. The galenic formulation will consist of drug loaded biodegradable polymer particles (e.g., chitosan, polylactic-co-glycolic acid, PLGA) embedded into a biodegradable hydrogel matrix (e.g., hyaluronic acid (HA)-based) to be deposited as a patch onto the olfactory region. A pH-sensitive, mucoadhesive particle coating (e.g., chitosan, chitosan derivatives) will ensure an environment-specific adhesion to the olfactory epithelium. This novel technology will largely enhance the controlled and sustainable delivery of drugs and increase the drug bioavailabilty to the CNS. NogoA antagonist NG-101 will be used as an active pharmaceutical ingredient (API). Proof of concept studies and initial clinical data have proven the enormous potential of blocking NogoA for spinal cord remyelation and axonal integrity. However, monoclonal antibodies (mAb) like NG-101, do not sufficiently cross the BBB. The sustainable and controlled release of NG-101 to the CNS will be achieved via the transport of embedded polymer particles to the olfactory epithelium, the subsequent release of API and permeation through the olfactory region, the only part of the nasal epithelium which is in direct contact with the brain. The direct transport route from the nasal cavity to the brain, bypassing the BBB, offers an exciting mode of central nervous system (CNS) drug delivery not only for demyelinating disorders but also for other CNS indications, e.g., stroke, neurodegenerative diseases or tumours. The proposed new innovative N2B drug delivery platform is a practical, safe, and minimally invasive technology. It will be exploited for NG-101 and has the potential to be implemented with other APIs with a low CNS bioavailability.
Funded Companies:
| Company name | Funding amount |
| BEITER GmbH GO KG | €728,125 |
| Contipro AS | €400,000 |
| Ethniko Kentro Erevnas Kai Technologikis Anaptyxis | €495,000 |
| FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG e. V. | €783,095 |
| HOCHSCHULE BIBERACH | €1,102,399 |
| Jensonr+ Ltd. | €611,700 |
| Laboratorio Europeo Di Spettroscopie NON Lineari | €227,500 |
| LGI Sustainable Innovation | €291,250 |
| MYBIOTECH GmbH | €559,138 |
| NOVAGO THERAPEUTICS AG | €0.00 |
| THE European Multiple Sclerosis Platform Aisbl | €127,293 |
| UNIVERSITAET BERN | €0.00 |
Source: https://cordis.europa.eu/project/id/721098
The filing refers to a past date, and does not necessarily reflect the current state.
The visualizations for "BEITER GmbH GO KG - EU funding (€5,325,499): Nose to Brain Delivery of Antibodies via the Olfactory Region for the Treatment of Multiple Sclerosis Using Novel Multi-functional Biomaterials Combined with a Medical Device"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
